Skip to main content
PMC home page
CNS Drug Reviews logoLink to CNS Drug Reviews
. 2006 Jun 7;9(4):359–374. doi: 10.1111/j.1527-3458.2003.tb00260.x

Pharmacology of Acamprosate: An Overview

Teodoro Zornoza 1, María J Cano 1, Ana Polache 1, Luis Granero 1,✉
PMCID: PMC6741676  PMID: 14647529

ABSTRACT

In the last years important advances have been made in the development of drugs for the treatment of alcohol addiction. Acamprosate (calcium bis‐acetylhomotaurine) is one of the better established drugs in this field on the European market. This review focuses first on the pharmacokinetics of acamprosate. The published data and the recent advances in our knowledge on the mechanisms involved in the intestinal absorption and elimination of this drug are summarized. The importance of pharmacokinetics for the proper clinical use of acamprosate is highlighted. The anti‐relapse as well as the well‐known effects of acamprosate on ethanol intake are discussed. The recent experiments in animal models of conditioned withdrawal are reviewed. These experiments, explored for the first time the anticraving effect of the drug. Finally, the proposed hypotheses on the neuropharmacological mechanism of action of acamprosate are discussed. The discussion deals with the relative importance of various hypotheses as well as with the recent experiments that support them. It is pointed out that further research is necessary in order to clearly understand the mode of action of acamprosate as well as the neurobiological mechanisms involved in alcohol dependence.

Keywords: Acamprosate, Alcoholism, Anticraving drugs, Drug addiction, Relapse

Full Text

The Full Text of this article is available as a PDF (117.4 KB).

References

  • 1. Allgaier C, Franke H, Sobottka H, Scheibler P. Acamprosate inhibits Ca2+ influx mediated by NMDA receptors and voltage‐sensitive Ca2+ channels in cultured rat mesencephalic neurones. Naunyn-Schmiedeberg's Arch Pharmacol 2000;362:440–443. [DOI] [PubMed] [Google Scholar]
  • 2. Al‐Qatari M, Bouchenafa O, Littleton J. Mechanism of action of acamprosate: Part II. Ethanol dependence modifies effects of acamprosate on NMDA receptor binding in membranes from rat cerebral cortex. Alcohol Clin Exp Res 1998;22:810–814. [PubMed] [Google Scholar]
  • 3. Al‐Qatari M, Khan S, Harris B, Littleton J. Acamprosate is neuroprotective against glutamate‐induced excitotoxicity when enhanced by ethanol withdrawal in neocortical cultures of fetal rat brain. Alcohol Clin Exp Res 2001;25:1276–1283. [DOI] [PubMed] [Google Scholar]
  • 4. Al‐Qatari M, Littleton J. Acamprosate inhibits the up‐regulation of calcium channels in rat brain associated with development of ethanol dependence. Alcohol Clin Exp Res 1996;20:92A. [Google Scholar]
  • 5. Anderberg EK, Lindmark T, Artursson P. Sodium caprate elicits dilatations in human intestinal tight junctions and enhances drug absorption by the paracellular route. Pharmac Res 1993;10:857–864. [DOI] [PubMed] [Google Scholar]
  • 6. Berton F, Francesconi W, Madamba S, Zieglgansberger W, Siggins GR. Acamprosate enhances NMDA receptor‐mediated neurotransmission but inhibits presynaptic GABAB receptors in nucleus accumbens neurons. Alcohol Clin Exp Res 1998;22:183–191. [PubMed] [Google Scholar]
  • 7. Blaha CD, Yang CR, Floresco SB, Barr AM, Phillips A. Stimulation of the ventral subiculum of the hippocampus evokes glutamate receptor‐mediated changes in dopamine efflux in the rat nucleus accumbens. Eur J Neurosci 1997;5:902–911. [DOI] [PubMed] [Google Scholar]
  • 8. Boismare F, Daoust M, Moore ND, et al. A homotaurine derivate reduces the voluntary intake of ethanol by rats. Are cerebral GABA receptors involved Pharmacol Biochem Behav 1984;21:787–789. [DOI] [PubMed] [Google Scholar]
  • 9. Brudzynski SM, Gibson CJ. Release of dopamine in the nucleus accumbens caused by stimulation of the subiculum in freely moving rats. Brain Res Bull 1997;42:303–308. [DOI] [PubMed] [Google Scholar]
  • 10. Cano‐Cebrián MJ, Zornoza‐Sabina T, Guerri C, Granero L, Polache A. Effect of non‐ionic surfactants (polysorbate 80) on the intestinal absorption of acamprosate in the rat. Alcohol Alcohol 2001;36:505. [Google Scholar]
  • 11. Cano‐Cebrián MJ, Zornoza‐Sabina T, Guerri C, Polache A, Granero L. Local acamprosate modulates dopamine release in the rat nucleus accumbens through NMDA receptors: an in vivo microdialysis study. Naunyn-Schmiedeberg's Arch Pharmacol 2003;367:119–125. [DOI] [PubMed] [Google Scholar]
  • 12. Chabenat C, Chretien P, Daoust M, et al. Physicochemical, pharmacological and pharmacokinetic study of a new gabaergic compound, calcium acetylhomotaurinate. Meth Find Exp Clin Pharmacol 1988;10:311–317. [PubMed] [Google Scholar]
  • 13. Cole JC, Littleton J, Little HJ. Effects of repeated ethanol administration in the plus maze; a simple model for conditioned abstinence behaviour. Psychopharmacology 1999;142:270–279. [DOI] [PubMed] [Google Scholar]
  • 14. Cole JC, Littleton J, Little HJ. Acamprosate, but not naltrexone, inhibits conditioned abstinence behaviour associated with repeated ethanol administration and exposure to a plus‐maze. Psychopharmacology 2000;147:403–411. [DOI] [PubMed] [Google Scholar]
  • 15. Czachowski CL, Legg BH, Samson HH. Effects of acamprosate on ethanol‐seeking and self‐administration in the rat. Alcohol Clin Exp Res 2001;25:344–350. [PubMed] [Google Scholar]
  • 16. Dahchour A, De Witte P, Bolo N, et al. Central effects of acamprosate: Part 1. Acamprosate blocks the glutamate increase in the nucleus accumbens microdialysate in ethanol withdrawn rats. Psychiatry Res Neuroimaging 1998;82:107–114. [DOI] [PubMed] [Google Scholar]
  • 17. Dahchour A, De Witte P. Acamprosate decreases the hypermotility during repeated ethanol withdrawal. Alcohol 1999;18:107–114. [DOI] [PubMed] [Google Scholar]
  • 18. Dahchour A, De Witte P. Effects of acamprosate on excitatory amino acids during multiple ethanol withdrawal periods. Alcohol Clin Exp Res 2003;27:465–470. [DOI] [PubMed] [Google Scholar]
  • 19. Daoust M, Legrand E, Gewiss M, et al. Acamprosate modulates synaptosomal GABA transmission in chronically alcoholised rats. Pharmacol Biochem Behav 1992;41:669–674. [DOI] [PubMed] [Google Scholar]
  • 20. Daoust M, Prevost M, Saligaut C, et al. Calcium bis acetyl homotaurine increases the number of GABA uptake sites in alcohol prefering rat hippocampus. Alcohol Alcohol 1986;21:A31. [Google Scholar]
  • 21. Durbin P, Belleville M. Rat pharmacokinetic profile of acamprosate in plasma, brain and CSF. Alcohol Alcohol 1995;30:548. [Google Scholar]
  • 22. Fadda F, Rossetti ZL. Chronic ethanol consumption: from neuroadaptation to neurodegeneration. Prog Neurobiol 1998;56:385–431. [DOI] [PubMed] [Google Scholar]
  • 23. Floresco SB, Todd CL, Grace AA. Glutamatergic afferents from the hippocampus to the nucleus accumbens regulate activity of ventral tegmental area dopamine neurons. J Neurosci 2001;21:4915–4922. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Gibaldi M. Gastrointestinal absorption‐Biological considerations In: Gibaldi M, ed. Biopharmaceutics and Clinical Pharmacokinetics. Philadelphia : Lea and Febiger, 1991:25–39. [Google Scholar]
  • 25. Grant KA, Woolverton D. Reinforcing and discriminative stimulus effects of calcium‐acetyl homotaurine in animals. Pharmacol Biochem Behav 1989;32:607–611. [DOI] [PubMed] [Google Scholar]
  • 26. Harris BR, Prendergast MA, Gibson A et al. Acamprosate inhibits the binding and neurotoxic effects of trans‐ACPD, suggesting a novel site of action at metabotropic glutamate receptors. Alcohol Clin Exp Res 2002;26:1779–1793. [DOI] [PubMed] [Google Scholar]
  • 27. He YL, Murby S, Warhurst G, et al. Species differences in size discrimination in the paracellular pathway reflected by oral bioavailability of polyethylene glycol and D‐peptides. J Pharm Sci 1998;87:626–633. [DOI] [PubMed] [Google Scholar]
  • 28. Heyser CJ, Moc K, Koob GF. Effects of naltrexone alone and in combination with acamprosate on the alcohol deprivation effect in rats. Neuropsychopharmacology 2003;28:1463–1471. [DOI] [PubMed] [Google Scholar]
  • 29. Heyser CJ, Schulteis G, Durbin P, Koob GF. Chronic acamprosate eliminates the alcohol deprivation effect while having limited effects on baseline responding for ethanol in rats. Neuropsychopharmacology 1998;18:125–133. [DOI] [PubMed] [Google Scholar]
  • 30. Hölter SM, Landgraf R, Zieglgansberger W, Spanagel R. Time course of acamprosate action on operant self‐administration after ethanol deprivation. Alcohol Clin Exp Res 1997;21:862–868. [PubMed] [Google Scholar]
  • 31. Johnson BA, Ait‐Daoud N. Neuropharmacological treatments for alcoholism: Scientific basis and clinical findings. Psychopharmacology 2000;149:327–344. [DOI] [PubMed] [Google Scholar]
  • 32. Johnson BA, O'Malley SS, Ciraulo DA, et al. Dose‐ranging kinetics and behavioral pharmacology of naltrexone and acamprosate, both alone and combined, in alcohol‐dependent subjects. J Clin Psychopharmacol 2003;23:281–293. [DOI] [PubMed] [Google Scholar]
  • 33. Kratzer U, Schmidt WJ. Acamprosate does not induce a conditioned place preference and reveals no state‐dependent effects in this paradigm. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:653–656. [DOI] [PubMed] [Google Scholar]
  • 34. Lê AD, Shaham Y. Neurobiology of relapse to alcohol in rats. Pharmacol Ther 2002;94:137–156. [DOI] [PubMed] [Google Scholar]
  • 35. Legault M, Rompré PP, Wise R. Chemical stimulation of the ventral hippocampus elevates nucleus accumbens dopamine by activating dopaminergic neurons of the ventral tegmental area. J Neurosci 2000;20:1635–1642. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36. Legault M, Wise R. Injections of N‐methyl‐D‐aspartate into the ventral hippocampus increase extracellular dopamine in the ventral tegmental area and nucleus accumbens. Synapse 1999;31:241–249. [DOI] [PubMed] [Google Scholar]
  • 37. LeMagnen J, Tran G, Durlach J, Martin C. Dose‐dependent supression of the high alcohol intake of chronically intoxicated rats by Ca‐acetylhomotaurinate. Alcohol 1987;4:97–102. [DOI] [PubMed] [Google Scholar]
  • 38. Lhuintre JP, Daoust M, Moore ND, et al. Ability of calcium bis acetyl homotaurine, a GABA agonist, to prevent relapse in weaned alcoholics. Lancet 1985;1 (8436): 1014–1016. [DOI] [PubMed] [Google Scholar]
  • 39. Lhuintre JP, Moore ND, Tran G, et al. Acamprosate appears to decrease alcohol intake in weaned alcoholics. Alcohol Alcohol 1990;25:613–622. [DOI] [PubMed] [Google Scholar]
  • 40. Lindmark T, Kimura Y, Artursson P. Absorption enhancement through intracellular regulation of tight junction permeability by medium chain fatty acids in Caco‐2 cells. J Pharmacol Exp Ther 1998;284:362–369. [PubMed] [Google Scholar]
  • 41. Littleton J. Acamprosate in alcohol dependence: How does it work Addiction 1995;90:1179–1188. [DOI] [PubMed] [Google Scholar]
  • 42. McGeehan AJ, Olive MF. The anti‐relapse compound acamprosate inhibits the development of a conditioned preference to ethanol and cocaine but not morphine. Br J Pharmacol 2003;138:9–12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43. Mas‐Serrano P, Granero L, Martín‐Algarra RV, Guerri C, Polache A. Kinetic study of acamprosate absorption in rat small intestine. Alcohol Alcohol 2000;4:324–330. [DOI] [PubMed] [Google Scholar]
  • 44. Mason BJ. Treatment of alcohol‐dependent outpatients with acamprosate: a clinical review. J Clin Psychiatry 2001;62 (Suppl 20): 42–48. [PubMed] [Google Scholar]
  • 45. Mason BJ, Goodman AM, Dixon RM, et al. A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone. Neuropsychopharmacology 2002;27:596–606. [DOI] [PubMed] [Google Scholar]
  • 46. Mayer S, Harris BR, Gibson A, et al. Acamprosate, MK‐801, and ifenprodil inhibit neurotoxicity and calcium entry induced by ethanol withdrawal in organotypic slice cultures from neonatal rat hippocampus. Alcohol Clin Exp Res 2002;26:1468–1478. [DOI] [PubMed] [Google Scholar]
  • 47. Naassila M, Hammoumi S, Legrand E, Durbin P, Daoust M. Mechanism of action of acamprosate: Part I. Characterization of spermidine‐sensitive acamprosate binding site in rat brain. Alcohol Clin Exp Res 1998;22:802–809. [PubMed] [Google Scholar]
  • 48. Olive MF, Nannini MA, Ou CJ, Koenig HN, Hodge CW. Effects of acute acamprosate and homotaurine on ethanol intake and ethanol‐stimulated mesolimbic dopamine release. Eur J Pharmacol 2002;437:55–61. [DOI] [PubMed] [Google Scholar]
  • 49. Putzke J, Spanagel R, Tolle TR, Zieglgansberger W. The anti‐craving drug acamprosate reduces c‐fos expression in rats undergoing ethanol withdrawal. Eur J Pharmacol 1996;317:39–48. [DOI] [PubMed] [Google Scholar]
  • 50. Quertemont E, Brabant C, De Witte P. Acamprosate reduces context‐dependent ethanol effects. Psychopharmacology 2002;164:10–18. [DOI] [PubMed] [Google Scholar]
  • 51. Rammes G, Mahal B, Putzke J, et al. The anti‐craving compound acamprosate acts as a weak NMDA‐receptor antagonist, but modulates NMDA‐receptor subunit expression similar to memantine and MK‐801. Neuropharmacology 2001;40:749–760. [DOI] [PubMed] [Google Scholar]
  • 52. Ripley TL, Little HJ. Effects on ethanol withdrawal hyperexcitability of chronic treatment with a competitive N‐methyl‐D‐aspartate receptor antagonist. J Pharmacol Exp Ther 1995;272:112–118. [PubMed] [Google Scholar]
  • 53. Rossetti ZL, Carboni S. Ethanol withdrawal is associated with increased extracellular glutamate in the rat striatum. Eur J Pharmacol 1995;283:177–183. [DOI] [PubMed] [Google Scholar]
  • 54. Saas H, Soyka M, Zieglgansberger W. Relapse prevention by acamprosate. Results from a placebo‐controlled study on alcohol dependence. Arch Gen Psychiatry 1996;53:673–680. [DOI] [PubMed] [Google Scholar]
  • 55. Saivin S, Hulot T, Chabac S, Potgieter A, Durbin P, Houin G. Clinical pharmacokinetics of acamprosate. Clin Pharmacokinet 1998;35:331–345. [DOI] [PubMed] [Google Scholar]
  • 56. Soyka M, Preuss U, Schuetz C. Use of acamprosate and different kinds of psychosocial support in relapse prevention of alcoholics. Results from a non‐blind, multicenter study. Drugs Res Dev 2002;3:1–12. [DOI] [PubMed] [Google Scholar]
  • 57. Spanagel R, Hölter SM. Pharmacological validation of a new animal model of alcoholism. J Neural Transm 2000;107:669–680. [DOI] [PubMed] [Google Scholar]
  • 58. Spanagel R, Hölter SM, Allingham K, Landgraf R. Acamprosate and alcohol: I. Effects on alcohol intake following alcohol deprivation in the rat. Eur J Pharmacol 1996;305:39–44. [DOI] [PubMed] [Google Scholar]
  • 59. Spanagel R, Zieglgansberger W, Hundt W. Acamprosate and alcohol: III. Effects on alcohol discrimination in the rat. Eur J Pharmacol 1996;305:51–56. [DOI] [PubMed] [Google Scholar]
  • 60. Spanagel R, Zieglgansberger W. Anti‐craving compounds for ethanol: New pharmacological tools to study addictive processes. Trends Pharmacol Sci 1997;18:54–59. [PubMed] [Google Scholar]
  • 61. Stromberg MF, Mackler SA, Volpicelli JR, O'Brien CP. Effect of acamprosate and naltrexone, alone or in combination, on ethanol consumption. Alcohol 2001;23:109–116. [DOI] [PubMed] [Google Scholar]
  • 62. Taepavarapruk P, Floresco SB, Phillips A. Hyperlocomotion and increased dopamine efflux in the rat nucleus accumbens evoked by electrical stimulation of the ventral subiculum: Role of ionotropic glutamate and dopamine D1 receptors. psychopharmacology 2000;151:242–251. [DOI] [PubMed] [Google Scholar]
  • 63. Weiss F, Porrino LJ. Behavioral neurobiology of alcohol addiction: Recent advances and challenges. J Neurosci 2002;22:3332–3337. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64. Whitworth AB. Comparison of acamprosate and placebo in long‐term treatment of alcohol dependence. Lancet 1996;347:1438–1442. [DOI] [PubMed] [Google Scholar]
  • 65. Wilde MI, Wagstaff AJ. Acamprosate. A review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification. Drugs 1997;56:1038–53. [DOI] [PubMed] [Google Scholar]
  • 66. Zeise ML, Kasparov S, Capogna M, Zieglgansberger W. Acamprosate decreases postsynaptic potentials in the rat neocortex: Possible role of excitatory amino acid receptors. Eur J Pharmacol 1993;23:47–52. [DOI] [PubMed] [Google Scholar]
  • 67. Zieglgansberger W, Hauser C, Wetzel C, Putzke J, Siggins GR, Spanagel R. Actions of acamprosate on neurons of the central nervous system In: Soyka M, ed. Acamprosate in relapse prevention of alcoholism. Berlin : Springer, 1996;65–70. [Google Scholar]
  • 68. Zornoza‐Sabina T, Cano‐Cebrián MJ, Guerri C, Granero L, Polache A. Enhancement of acamprosate intestinal absorption by sodium caprate in the rat. Alcohol Alcohol 2001;36:469. [Google Scholar]
  • 69. Zornoza T, Guerri C, Polache A, Granero L. Disposition of acamprosate in the rat: influence of probenecid. Biopharm Drug Dispos 2002;23:283–291. [DOI] [PubMed] [Google Scholar]

Articles from CNS Drug Reviews are provided here courtesy of Wiley

RESOURCES